Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia

Simple item page
dc.contributor.affiliationLaboratorio de Psicoinmunología, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz, Mexico City 14370, Mexico
dc.contributor.emaillkuriaki@inprf.gob.mx (Pavón, Lenin)
dc.creatorAlvarez-Herrera, Samantha
dc.creatorRosel Vales, Mauricio
dc.creatorPérez-Sánchez, Gilberto
dc.creatorBecerril-Villanueva, Enrique
dc.creatorFlores-Medina, Yvonne
dc.creatorMaldonado-García, José Luis
dc.creatorSaracco-Alvarez, Ricardo
dc.creatorEscamilla, Raúl
dc.creatorPavón, Lenin
dc.creator.identificadorhttps://orcid.org/0000-0001-9747-885X (Alvarez-Herrera, Samantha)
dc.creator.identificadorhttps://orcid.org/0000-0003-3878-0631 (Pérez-Sánchez, Gilberto)
dc.creator.identificadorhttps://orcid.org/0000-0003-2694-1290 (Maldonado-García, José Luis)
dc.date2024
dc.date.accessioned2026-06-23T19:26:26Z
dc.date.issued2024
dc.date.published2024
dc.descriptionDopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. Each antipsychotic induces a unique pattern in leukocyte function and phenotype. However, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (PBMCs). The aim of this study was to evaluate the changes in the expression of D3, D5, DAT, 5-HT2A, and SERT in PBMCs from healthy volunteers (HV), drug-naive patients with schizophrenia (PWS), drug-free PWS, and PWS treated with risperidone for up to 40 weeks using quantitative PCR. Our study revealed elevated mRNA levels of D3, DAT, 5-HT2A, and SERT in unmedicated PWS. Treatment with risperidone led to a reduction only in the expression of 5-HT2A and SERT. Furthermore, we observed a moderate correlation between 5-HT2A expression and the positive and negative syndrome scale (PANSS), as well as SERT expression and PANSS scale. We also found a moderate correlation between 5-HT2A and SERT expression and the positive subscale. The duration of risperidone consumption had a significant negative correlation with the expression of 5-HT2A and SERT. Our study introduces the measurement of 5-HT2A and SERT expression in PBMCs as a useful parameter for assessing the response to risperidone in PWS.
dc.formatPDF
dc.identifierJC31NC24
dc.identifier.doi10.3390/ph17020167
dc.identifier.eissn1424-8247
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.placeSuiza
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/136
dc.identifier.urihttps://doi.org/10.3390/ph17020167
dc.language.isoeng
dc.publisherMDPI
dc.relation17(2):167
dc.relation.jnabreviadoPHARMACEUTICALS (BASEL)
dc.relation.journalPharmaceuticals
dc.rightsAcceso Cerrado
dc.subject.kwSchizophrenia
dc.subject.kwDopamine receptors
dc.subject.kwSerotonin receptors
dc.subject.kwDopamine transporter
dc.subject.kwSerotonin transporter
dc.subject.kwRisperidone
dc.titleRisperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia
dc.typeArtículo

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista